Eric Dane’s passing has put a harsh spotlight back on amyotrophic lateral sclerosis, commonly called ALS or Lou Gehrig’s disease, and the brutal speed with which it can rob people of basic abilities. The diagnosis timeline, the limited treatments, and the push for far more research funding are all part of the conversation now. This piece lays out what ALS does, how it’s diagnosed, and why advocates say more investment is urgently needed.
ALS, short for amyotrophic lateral sclerosis, attacks the nerve cells that control voluntary muscles and eventually strips away functions like walking, speaking, eating and breathing. Only about 5,000 people in the United States are diagnosed each year, and the ALS Association reports an average life expectancy of two to five years after diagnosis. Early signs include muscle weakness, stiffness and cramping, but the pace and pattern of decline vary widely from person to person.
Dane first went public with his diagnosis in April 2025 and described early symptoms that felt minor at first. “I didn’t really think anything of it,” the actor said. “At the time, I thought maybe I’d been texting too much, or my hand was fatigued. But a few weeks later, I noticed that it got a little worse.”
“I’m fighting as much as I can,” Dane added. “There’s so much about it that’s out of my control.” Those words underline a common experience: patients try to act, treat symptoms and hold on to control while a relentless disease advances in ways medicine still struggles to stop.
The illness targets the motor neurons that carry signals from the brain to muscles, and as those connections fail a person loses the ability to move and eventually to breathe. The five senses, bladder control and eye muscles are typically spared, and many patients remain mentally clear and aware even as their bodies decline. That gulf between a trapped body and a clear mind is one of the cruelest aspects of ALS.
Diagnosis most often arrives between ages 40 and 70 and generally involves tests like electromyography along with blood or urine tests, spinal taps and imaging scans when needed. There is no one-size-fits-all timeline for ALS, and while about 20% of patients live five years or longer, only roughly 5% exceed two decades. Because progression is so variable, early detection and symptom management matter for planning care.
Treatments today can ease symptoms and sometimes slow progression, but there is no cure that halts the disease. That gap drives families and clinicians toward palliative strategies and adaptive technologies that preserve independence as long as possible. The cost of long-term care is substantial, and many caregivers quickly become full-time coordinators of complex medical needs.
Medical voices have raised the question of what triggers most noninherited cases. While roughly 10% of ALS is linked to genetic causes, the remaining 90% lacks an obvious inherited origin, which has led experts to point at environmental or other risk factors. “It’s a muscle weakness disease — affecting nerves that innervate muscles — and usually it starts on one side,” one physician explained. “Then you develop fatigue … You could see a quivering tongue or your arm is quivering, usually one side and then the other side.”
As the disease advances it often moves from limb weakness into speech and swallowing problems, and ultimately attacks the diaphragm, reducing the ability to fully inflate the lungs. “That’s what happened to [Dane], most likely,” the doctor said. ALS progresses “pretty rapidly in most cases,” he added, noting exceptions like Stephen Hawking, and observing that Dane “probably lived about two years with it.”
Beyond clinical descriptions, there’s a push to fund targeted research and personalized therapies. “I want to point out how courageous [Dane] is — he actually was involved with Target ALS, where he was fighting for new research,” the physician pointed out. “We’re learning to personalize the approach to this disease, and that’s the future — and he fought for that.” The same expert stressed the scale of the problem: “We need a lot of money for research for this — [Dane] was asking for a billion dollars from the government.”
Drug development and care expenses add up fast: estimates peg the cost to develop a drug that could slow or stop progression near $2 billion, while annual care can reach roughly $250,000 per patient. Public fundraising and awareness campaigns have moved the needle before — the viral Ice Bucket Challenge in 2014 raised significant dollars — but advocates say sustained, larger-scale investment is required to translate promising science into real treatments.
